The Discovery of Setileuton, a Potent and Selective 5-Lipoxygenase Inhibitor
ACS Medicinal Chemistry Letters2010Vol. 1(4), pp. 170–174
Citations Over TimeTop 10% of 2010 papers
Yves Ducharme, Marc Blouin, Christine Brideau, Anne Châteauneuf, Yves Gareau, Erich L. Grimm, Hélène Jûteau, Sébastien Laliberté, Bruce Mackay, Frédéric Massé, Marc Ouellet, Myriam Salem, Angela Styhler, Richard W. Friesen
Abstract
The discovery of novel and selective inhibitors of human 5-lipoxygenase (5-LO) is described. These compounds are potent, orally bioavailable, and active at inhibiting leukotriene biosynthesis in vivo in a dog PK/PD model. A major focus of the optimization process was to reduce affinity for the human ether-a-go-go gene potassium channel while preserving inhibitory potency on 5-LO. These efforts led to the identification of inhibitor (S)-16 (MK-0633, setileuton), a compound selected for clinical development for the treatment of respiratory diseases.
Related Papers
- → Application of Emax model to assess the potency of topical corticosteroid products(2022)4 cited
- → Establishment of a Potency Test by ELISA for a Rabies Vaccine for Animal Use in Japan(2003)15 cited
- → STANDARDIZATION OF ANTIVENINE I. A METHOD FOR DETERMINATION OF ANTILETHAL POTENCY OF HABU ANTIVENINE(1965)19 cited
- → The Experimental Study on the continuous Anti-bacterial Potency of Coptidis rhizoma extract on Cultivation of Staphylococcus species(S. aureus, S. epidermidis)(2007)1 cited
- → Potency analysis of cellular therapies: the role of molecular assays(2021)